These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24419335)

  • 1. New strategies for relapsed acute myeloid leukemia: fertile ground for translational research.
    Dinner SN; Giles FJ; Altman JK
    Curr Opin Hematol; 2014 Mar; 21(2):79-86. PubMed ID: 24419335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted therapy in acute myeloid leukemia.
    Gill H; Leung AY; Kwong YL
    Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.
    Reikvam H; Hoang TT; Bruserud Ø
    Expert Rev Hematol; 2015 Jun; 8(3):315-27. PubMed ID: 25901742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia with DNMT3A mutations.
    Li Y; Zhu B
    Leuk Lymphoma; 2014 Sep; 55(9):2002-12. PubMed ID: 24283755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New agents for the treatment of acute myeloid leukemia.
    Tallman MS
    Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.
    Zeng Z; Liu W; Tsao T; Qiu Y; Zhao Y; Samudio I; Sarbassov DD; Kornblau SM; Baggerly KA; Kantarjian HM; Konopleva M; Andreeff M
    Haematologica; 2017 Sep; 102(9):1537-1548. PubMed ID: 28659338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy of acute myeloid leukemia.
    Carneiro BA; Altman JK; Kaplan JB; Ossenkoppele G; Swords R; Platanias LC; Giles FJ
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):399-413. PubMed ID: 25623136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis.
    Eriksson A; Lennartsson A; Lehmann S
    Exp Hematol; 2015 Aug; 43(8):609-24. PubMed ID: 26118500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia: Therapy resistance and a potential role for tetraspanin membrane scaffolds.
    Floren M; Gillette JM
    Int J Biochem Cell Biol; 2021 Aug; 137():106029. PubMed ID: 34174403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
    Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
    Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
    Hou HA; Tien HF
    Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia.
    Nebbioso A; Benedetti R; Conte M; Iside C; Altucci L
    Expert Opin Ther Targets; 2015; 19(9):1187-202. PubMed ID: 26028314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The increasing genomic complexity of acute myeloid leukemia.
    Rowe JM
    Best Pract Res Clin Haematol; 2014; 27(3-4):209-13. PubMed ID: 25455268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.
    Bruserud Ø; Aasebø E; Hernandez-Valladares M; Tsykunova G; Reikvam H
    Expert Opin Drug Discov; 2017 Oct; 12(10):1053-1065. PubMed ID: 28748730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic agents in acute myeloid leukemia.
    Stone RM
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):163-6. PubMed ID: 17379102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia.
    Newcombe AA; Gibson BES; Keeshan K
    Exp Hematol; 2018 Jul; 63():1-11. PubMed ID: 29608923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular pathogenesis of acute myeloid leukemia.
    Steffen B; Müller-Tidow C; Schwäble J; Berdel WE; Serve H
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):195-221. PubMed ID: 16236521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel strategies for relapsed and refractory acute myeloid leukemia.
    Mato AR; Morgans A; Luger SM
    Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?
    Reikvam H; Kittang AO; Melve G; Mosevoll KA; Bentsen PT; Ersvær E; Gjertsen BT; Bruserud Ø
    Curr Cancer Drug Targets; 2013 Jan; 13(1):30-47. PubMed ID: 22873213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.